uBiome Releases New Explorer™ Story to Help Consumers Understand Sleep Quality
SAN FRANCISCO, Jan. 9, 2019
SAN FRANCISCO, Jan. 9, 2019 /PRNewswire-PRWeb/ -- uBiome, the leader in microbial genomics, announced today the release of a new Explorer™ story which provides insights to help individuals understand how their gut microbes offer support in improving sleep quality.
The microbiome may play a role in sleep disruptions, which if reoccurring, may lead to diseases such as obesity and diabetes. Research shows that various bacteria produce neurotransmitters that are involved in natural sleep rhythms, such as serotonin and Gamma-Aminobutyric acid (GABA). The new story provides an individualized abundance of these bacteria and ways to take action for improved sleep quality.
"Recent research suggests that the microscopic inhabitants that live in and on our bodies, specifically how well we get to sleep and stay asleep," Dr. Jessica Richman, PhD, co-founder and CEO of uBiome, said. "uBiome is proud to utilize the latest science to expand the insights Explorer offers to consumers."
Since its launch in 2013, Explorer, uBiome's pioneer product, has provided consumers with a tool to understand how their diet and lifestyle play a role in their health and wellness. It is the world's first microbiome test to use next-generation sequencing, allowing consumers to learn about their microbiomes from the comfort of their homes. With the health and wellness market surpassing $37 trillion globally, Explorer targets biohackers, fitness enthusiasts, and consumers interested in a comprehensive breakdown of their microbiome, how it's functioning, and how it compares to others. Explorer currently offers information on how microbes may alter gluten sensitivity, inflammation, lactose intolerance, healthy weight, and metabolism. To learn more about your own microbiome, visit https://ubiome.com/consumer/ubiome-explorer/.
Founded in 2012, uBiome is the leader in microbial genomics. The Company's mission is to advance the science of the microbiome and make it useful to people. uBiome combines its patented proprietary precision sequencing™ with machine learning and artificial intelligence to develop wellness products, clinical tests, and therapeutic targets. uBiome has filed for over 250 patents on its technology, which includes sample preparation, computational analysis, molecular techniques, as well as diagnostic and therapeutic applications.
uBiome's commercial products include SmartGut™, the world's first sequencing-based clinical microbiome test, which identifies microbes in the gut for patients with chronic gut conditions such as IBD, IBS, Crohn's Disease, and ulcerative colitis; SmartJane™, the first sequencing-based women's health screening test, which genotypes all 19 clinically relevant strains of HPV, identifies four common STDs, and surveys more than 20 vaginal microbes associated with bacterial vaginosis and other conditions; SmartFlu™, the world's first sequencing-based clinical respiratory test, which identifies more than 20 clinically relevant targets for viruses and bacteria associated with the flu and common cold; and Explorer™, a health and wellness product to understand the role that food and lifestyle can play in wellness.
uBiome's platform has been used by hundreds of thousands of consumers, patients, and doctors and more than 200 research institutions around the world, including the US Centers for Disease Control (CDC), US National Institutes of Health (NIH), Harvard University, Stanford University, the Massachusetts Institute of Technology (MIT), University of California, San Francisco, Oxford University, and the University of Sydney.
Since its launch, the company has received widespread recognition including CNN 10: Startups to Watch, the IVY Technology Award, CNN Future 30, and was named one of Fast Company's Most Innovative Companies in Healthcare in 2016 and in Data Science in 2018, as well as a Technology Pioneer from the World Economic Forum in 2018. For more information, visit http://www.uBiome.com.